Key facts
- Lupin and Natco Pharma received U.S. FDA approval for Eribulin Mesylate Injection.
- Eribulin Mesylate Injection is used for treating certain types of cancer.
Global pharmaceutical companies Lupin Limited and Natco Pharma Limited have announced the approval of their Eribulin Mesylate Injection by the United States Food and Drug Administration (FDA). This drug is indicated for the treatment of certain types of cancer. The approval marks a significant milestone for both companies in expanding their oncology portfolio and providing access to important treatments for patients in the United States.